eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
1/2022
vol. 60
 
Share:
Share:
more
 
 
abstract:
Original paper

Effect of 5-HT 1b/1d agonist on ethanol withdrawal syndrome and ethanol withdrawal induced anxiety

Jiarong Tian
1
,
Mingzhu Yan
2
,
Alok Shiomurti Tripathi
3
,
Dunbao Sun
1

1.
Department of Psychiatry, Ankang Central Hospital, Ankang, China
2.
Department of Neurology, Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi, China
3.
Department of Pharmacology, Amity Institute of Pharmacy, Amity University, Noida (U.P.), India
Folia Neuropathol 2022; 60 (1): 69-75
Online publish date: 2022/03/29
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Ethanol dependence and abuse is an important problem of public health worldwide and its withdrawal shows some severe behavioural complication. Management of ethanol withdrawal syndrome (EWS) is still a challenge, thus the presented report postulates the possible mechanism involved in the development of EWS.

Material and methods
EWS was induced by administration of ethanol for 21 days and 5-hydroxytryptamine (5-HT) 1b/1d agonist treated group receives Zolmitriptan (ZMT) at 30 mg/kg i.p. 30 min prior to ethanol withdrawal. The effect of 5-HT 1b/1d receptor agonist on EWS was determined by estimating the change in the behaviour of withdrawal signs that included locomotor hyperactivity, agitation, tremor, tail stiffness, stereotyped behaviour, and wet dog shakes at 1, 2, 4, 6 and 12 h of ethanol withdrawal. Ethanol withdrawal induced anxiety was determined by using the elevated plus maze and levels of neurochemicals such as g-aminobutyric acid (GABA), glutamate and dopamine were determined in the brain of each group of rats.

Results
Data of the given report reveal that Zolmitriptan reverses (p < 0.01) the behavioural changes induced due to EWS and also reduces the anxiety level in EWS rats. Moreover, Zolmitriptan was found to stimulate (p < 0.01) the level of GABA and ameliorate the level of other neurochemicals in the brain of EWS rats.

Conclusions
In conclusion, data of investigation reveal that 5-HT 1b/1d receptor involved in the EWS and treatment with its agonist prevents the behavioural changes in EWS by regulating the level of different neurochemicals.

keywords:

ethanol withdrawal syndrome, 5-hydroxytryptamine 1b/1d receptor, Zolmitriptan, GABA

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.